Platinum chromium stent series - The TAXUS™ element™ (ION™), PROMUS element™ and OMEGA™ stents

Interventional Cardiology: Reviews, Research, Resources

Volumn 6, Issue 2, 2011, Pages 134-141

  Allocco, Dominic J ^a   Jacoski, Mary V ^a   Huibregtse, Barbara ^a   Mickley, Tim ^a   Dawkins, Keith D ^a  

^a BOSTON SCIENTIFIC CORPORATION   (United States)

Author keywords

Bare metal stent; Drug eluting stent; Everolimus; Paclitaxel; Percutaneous coronary intervention

Indexed keywords

ARTICLE; BARE METAL STENT; CLINICAL OUTCOME; DEVICE APPROVAL; DRUG ELUTING STENT; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTICENTER STUDY (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PLATINUM CHROMIUM STENT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 85017370740     PISSN: 17561477     EISSN: 17561485     Source Type: Journal    
DOI: 10.15420/icr.2011.6.2.134     Document Type: Article

References (28)

1. Kereiakes DJ, Cox DA, Hermiller JB, et al. Usefulness of a cobalt chromium coronary stent alloy, Am J Cardiol 2003;92:463-6
2. Menown IB, Noad R, Garcia EJ, Meredith I, The platinum chromium element stent platform: from alloy, to design, to clinical practice, Adv Ther, 2010;27:129-41
3. Wilson GJ, Huibregtse BA, Stejskal EA, et al. Vascular response to a third generation everolimus-eluting stent, EuroIntervention, 2010;6:512-9
4. Allocco DJ, Cannon LA, Britt A, et al. A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxeleluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program, Trials, 2010;11:1
5. Turco MA, Ormiston JA, Popma JJ, et al. Polymer-based, paclitaxel-eluting TAXUS Liberte stent in de novo lesions: The Pivotal TAXUS ATLAS Trial, J Am Coll Cardiol, 2007;49:1676-83
6. Schiff PB, Fant J, Horwitz SB, Promotion of microtubule assembly in vitro by taxol, Nature, 1979;277:665-7
7. Rowinsky EK, Donehower RC, Paclitaxel (taxol), N Engl J Med, 1995;332:1004-14
8. Sollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat, J Clin Invest, 1995;95:1869-76
9. Certican [package insert], Novartis Pharmaceuticals Australia Pty Limited. Downloaded from Novartis Australia Website on 18 June 2008
10. Marx SO, Marks AR, Bench to bedside: the development of rapamycin and its application to stent restenosis, Circulation, 2001;104:852-5
11. Grube E, Buellesfeld L, Rapamycin analogs for stent-based local drug delivery. Everolimus-and tacrolimus-eluting stents, Herz, 2004;29:162-6
12. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents, J Am Coll Cardiol, 2008;52:333-42
13. Soucy NV, Feygin JM, Tunstall R, et al. Strut tissue coverage and endothelial cell coverage: a comparison between bare metal stent platforms and platinum chromium stents with and without everolimus-eluting coating, EuroIntervention, 2010;6:630-7
14. Stone GW, Ellis SG, Colombo A, et al. Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS clinical trial program, JACC Cardiovasc Interv, 2011;4:530-42
15. Kereiakes DJ, Cannon LA, Feldman RL, et al. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial, J Am Coll Cardiol, 2010;56:264-71
16. Cannon LA, Kereiakes DJ, Mann T, et al. A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERSEUS Small Vessel trial, EuroIntervention, 2011;6:920-7
17. Stone GW, Comparison of everolimus-eluting and paclitaxeleluting stents: First report of the four-year clinical outcomes from the SPIRIT III Trial, TCT, Washington, DC 2010
18. Caixeta A, Lansky AJ, Serruys PW, et al. Clinical follow-up 3 years after everolimus-and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials, JACC Cardiovasc Interv, 2010;3:1220-8
19. Serruys P, Ong A, Piek J, et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial, EuroIntervention, 2005;1:58-65
20. Wiemer M, Serruys PW, Miquel-Hebert K, et al. Five-year longterm clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT FIRST trial, Wiley Subscription Services, Inc., A Wiley Company
21. Ruygrok P, Desaga M, Van Den Braden F, et al. One year clinical follow-up of the XIENCE V everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study, EuroIntervention, 2007;3:315-20
22. Garg S, Serruys PW, Miquel-Hebert K, Four year clinical follow up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial. Wiley Subscription Services, Inc., A Wiley Company, 2010
23. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial, JAMA, 2008;299:1903-13
24. Nikolsky E, Lansky AJ, Sudhir K, et al. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease, Am Heart J, 2009;158:520-6 e522
25. Stone GW, Rizvi A, Sudhir K, et al. Randomized comparison of everolimus-and paclitaxel-eluting stents 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial, J Am Coll Cardiol, 2011 Apr
26. Meredith IT, Whitbourn R, Scott D, et al. PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses, EuroIntervention, 2011;7:84-90
27. Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent. The PLATINUM (A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of up to Two De Novo Coronary Artery Lesions) trial, J Am Coll Cardiol, 2011;57:1700-8
28. Meredith I, PLATINUM Small Vessel: 12-month outcomes. Presented at EuroPCR 2011, Paris, France, 2011